Group 1 - Kanglong Chemical fell by 3.18% [1] - Kelaiying decreased by 3.17% [1] - Zhaoyan New Drug dropped by 2.9% [1] - WuXi AppTec and Medisi both declined over 3% [1]

Group 1 - The A-share market saw a widespread decline in pharmaceutical stocks, with notable drops including Sunflower, Hanyu Pharmaceutical, and Kailaiying, each falling over 3% [1] - The U.S. President announced a new round of high tariffs on various imported products, including a 100% tariff on all brands and patented pharmaceutical products starting October 1 [1] Group 2 - Specific stock performance data shows that ST Complex dropped by 4.98%, with a total market value of 3.886 billion, and a year-to-date decline of 12.94% [2] - Sunflower's market value is 11.1 billion, with a year-to-date increase of 166.98%, despite a recent drop of 3.89% [2] - Hanyu Pharmaceutical's market value stands at 19.8 billion, with a year-to-date increase of 73.62%, and a recent decline of 3.20% [2] - Kailaiying's market value is 39.1 billion, with a year-to-date increase of 44.26%, and a recent drop of 3.01% [2] - Other companies such as Maiwei Bio, Zhaoyan New Drug, and Kanglong Chemical also experienced declines of over 2% [1][2]

Group 1 - Fidelity Funds reduced its stake in Zhaoyan New Drug (603127) by 445,700 shares at a price of HKD 24.3867 per share, totaling approximately HKD 10.8692 million [1] - After the reduction, Fidelity Funds holds 7.1303 million shares, representing a holding percentage of 5.99% [1]

Core Viewpoint - Fidelity Funds reduced its stake in Zhaoyan New Drug (06127) by 445,700 shares at a price of HKD 24.3867 per share, totaling approximately HKD 10.8692 million, resulting in a new holding of 7.1303 million shares, representing 5.99% of the company [1] Summary by Category - **Share Reduction** - Fidelity Funds decreased its holdings by 445,700 shares [1] - The transaction price was HKD 24.3867 per share [1] - Total amount from the reduction was approximately HKD 10.8692 million [1] - **Current Holdings** - After the reduction, Fidelity Funds holds 7.1303 million shares [1] - The new holding percentage is 5.99% [1]

Group 1 - The CRO concept stocks experienced significant fluctuations, with JiuZhou Pharmaceutical hitting the daily limit up [1] - ProLogis Pharmaceutical rose over 5%, indicating strong market interest [1] - Other companies such as Zhaoyan New Drug, Kangpeng Technology, Aopu Mai, and Haoyuan Pharmaceutical also saw increases in their stock prices [1]

Group 1 - The CRO index experienced an intraday increase of 2.01%, indicating strong market performance in the sector [1] - Jiuzhou Pharmaceutical reached its daily limit up, showcasing significant investor interest [1] - Zhaoyan New Drug and Aopu Mai saw respective increases of 3.49% and 3.40%, reflecting positive momentum among key players [1] - WuXi AppTec and Kelai Ying both recorded gains exceeding 2.5%, further highlighting the active performance of the CRO sector [1]

Group 1 - The core point of the article is that Zhaoyan New Drug (6127.HK) has seen a 4.17% increase in its stock price, reaching HKD 23.46, with a market capitalization of HKD 17.57 billion [2] - The company has announced a collaboration with professional investment institutions to establish an industrial fund [2] - Zhaoyan New Drug has received notification from China Merchants Capital Management (Beijing) Co., Ltd. that the fund has completed the private investment fund registration with the Asset Management Association of China and has obtained the Private Investment Fund Registration Certificate [2]

证券简称：昭衍新药 证券代码：603127 公告编号：2025-041 北京昭衍新药研究中心股份有限公司 关于与专业投资机构合作参与投资设立产业基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、与专业投资机构合作参与投资设立产业基金情况概述 北京昭衍新药研究中心股份有限公司（以下简称"昭衍新药"、"公司"）于 2024 年 10 月 30 日召开第四届董事会第十次会议，审议通过了《关于公司与专业投资 机构合作参与投资设立产业基金的议案》，同意公司或其指定子公司以不超过 1 亿元人民币投资参与服务贸易创新发展引导基金二期（有限合伙）（以下简称"本 基金"、"合伙企业"）的发起设立。招商局资本管理（北京）有限公司为本基 金的普通合伙人、执行事务合伙人，并担任本基金的基金管理人。具体内容详见 公司于 2024 年 10 月 31 日在上海证券交易所网站（www.sse.com.cn）及指定信 息披露媒体《上海证券报》披露的《昭衍新药关于与专业投资机构合作参与投资 设立产业基金的公告》（公告编号：2024-050）。 ...

格隆汇9月23日丨昭衍新药(06127.HK)公告，有关公司与专业投资机构合作参与投资设立产业基金事 项。近日，公司收到招商局资本管理(北京)有限公司的通知，本基金已在中国证券投资基金业协会完成 私募投资基金备案登记手续，并取得《私募投资基金备案证明》，备案信息如下： 3．托管人名称：招商银行股份有限公司 4．备案编码：SBGB42 5．备案日期：2025年9月21日 1．基金名称：服务贸易创新发展引导基金二期(有限合伙) 2．管理人名称：招商局资本管理(北京)有限公司 ...

Group 1 - The cell immunotherapy sector experienced a decline of 2.75%, ranking among the top losers in the concept sector, with ST Zhongzhu hitting the daily limit down [1] - Major stocks within the cell immunotherapy sector that saw significant declines include Zhaoyan New Drug, Jimin Health, and Boteng Co., with respective drops of 6.04%, 5.45%, and 5.34% [1][2] - The sector faced a net outflow of 1.61 billion yuan from main funds, with 48 stocks experiencing outflows, and six stocks seeing outflows exceeding 100 million yuan, led by Hengrui Medicine with a net outflow of 293 million yuan [2] Group 2 - The top gainers in today's concept sectors included the SMIC concept with a rise of 1.22% and the National Big Fund holding with an increase of 1.08% [2] - The main inflows were observed in stocks such as Betta Pharmaceuticals, Chutian Technology, and Rongchang Bio, with net inflows of 35.97 million yuan, 21.30 million yuan, and 14.08 million yuan respectively [4] - The overall market sentiment reflected a mixed performance across various sectors, with notable declines in the Huawei Pangu and MLOps concepts, down 3.69% and 3.31% respectively [2]